Clinical Trials Browser

INDUSTRY × monalizumab × Clear all

NCT04590963 2026-03-13

INTERLINK-1

Phase 3 Active not recruiting

370 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT05061550 2026-03-11

NeoCOAST-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05221840 2026-01-27

PACIFIC-9

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02671435 2025-07-22

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Phase 1/2 Active not recruiting

383 enrolled 48 charts

Neoplasm Metastasis

NCT03822351 2024-10-08

COAST

Phase 2 Completed

189 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02643550 2023-05-12

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1/2 Completed

Head and Neck Neoplasms

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Phase 2 Completed

84 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04145193 2020-09-21

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT02557516 2019-12-17

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

Phase 1/2 Terminated

22 enrolled 16 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell